M5049

selective TLR7/8 inhibitor (dimer stabilizer)

in Ph. I for lupus (oral twice-daily)

from screening for TLR7/8-selective agents

J. Pharmacol. Exp. Ther., Mar. 1, 2021

EMD Serono/Merck KGaA, Billerica, MA

11. The EMD Serono/Merck KGaA toll-like receptors TLR7/TLR8 inhibitor M5049 is an oral, twice-daily anti-inflammatory agent currently in a Ph. I trial for Lupus. The molecule potently blocks both…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks